The Center for the Biology of Chronic Disease (CBCD) announces the publication of a new study. The study is using the microcompetition model to explain how the latent cytomegalovirus (CMV) increases all-cause mortality.
The implication of this study is staggering. Almost everyone is infected with a latent virus, such as the CMV, EBV, HPV, HSV, and others, and therefore, almost everyone gets sick and dies too soon. You can find the viruses hiding in your body by a simple blood test.
What does it mean “hiding in your body”? This means that the virus does not cause any easy to recognize symptoms, such as fever, weakness, headache, pain, etc. However, silently, it causes your organs to fail.
The study was published in the important peer-reviewed medical journal Antiviral Therapy (1). The paper is listed on PubMed, and is available at https://pubmed.ncbi.nlm.nih.gov/33616550/
Also, since almost everyone is infected by a latent virus, why only some develop a major disease? And why some develop a disease sooner then others? According to the paper, the answer centers on the viral copy number. The higher the number of viral genomes hiding in your body, the more likely they will cause the development of a major disease sooner.
Recently, Dr. Hanan Polansky and his team published many studies showing how latent viruses cause major diseases. See for instance (2, 3, and 4)
Is there a treatment against latent viruses? The CBCD clinically tested two antiviral treatments: Gene-Eden-VIR and Novirin. These tests showed that the two natural treatments are effective against several viruses, including HPV, HSV, CMV, and EBV. The results of the clinical tests were published in important peer-reviewed journals. See, for instance (5, 6, 7 and 8).
To summarize, almost everyone is infected with a latent virus. Therefore, almost everyone could live longer by controlling the latent viruses in their body.
(1) Polansky, H. How can the latent cytomegalovirus cause an increase in all-cause mortality? An answer based on the microcompetition model. Antivir Ther. 2021 Feb 22. doi: 10.3851/IMP3384. Online ahead of print.
(2) Polansky H, Lori G. How microcompetition with latent viruses can cause α synuclein aggregation, mitochondrial dysfunction, and eventually Parkinson’s disease. J Neurovirol. 2021 Jan 6. doi: 10.1007/s13365-020-00929-x. Epub ahead of print. PMID: 33405201.
(3) Polansky H, Schwab H. How latent viruses cause breast cancer: An explanation based on the microcompetition model. Bosn J Basic Med Sci. 2019 Aug 20;19(3):221-226. doi: 10.17305/bjbms.2018.3950. PMID: 30579323; PMCID: PMC6716096.
(4) Polansky H, Schwab H. Copy number of latent viruses, oncogenicity, and the microcompetition model. Oncotarget. 2018 Aug 3;9(60):31568-31569. doi: 10.18632/oncotarget.25804. PMID: 30167078; PMCID: PMC6114963.
(5) Polansky H, Itzkovitz E, Javaherian A. Human papillomavirus (HPV): systemic treatment with Gene-Eden-VIR/Novirin safely and effectively clears virus. Drug Des Devel Ther. 2017 March 3, 11: 575—583;10:2713-22
(6) Polansky H, Itzkovitz E, Javaherian A. Clinical study of Gene-Eden-VIR/Novirin in genital herpes: suppressive treatment safely decreases the duration of outbreaks in both severe and mild cases. Clin Transl Med. 2016 Dec;5(1):40.
(7) Polansky, H. Javaherian, A. Itzkovitz E. Clinical study in genital herpes: natural Gene-Eden-VIR/Novirin versus acyclovir, valacyclovir, and Famciclovir. Drug Design, Development and Therapy 2016:10 2713-2722
(8) Polansky H, Itzkovitz E. Gene-Eden-VIR is antiviral: results of a post marketing clinical study. Pharmacol Pharm. 2013;4(6A):1-8